|
References1. Andresen, J.M., et al., Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds. J Med Genet, 2007. 44(1): p. 44-50. 2. Turek-Plewa, J. and P.P. Jagodzinski, The role of mammalian DNA methyltransferases in the regulation of gene expression. Cell Mol Biol Lett, 2005. 10(4): p. 631-47. 3. Feinberg, A.P., Cancer epigenetics takes center stage. Proc Natl Acad Sci U S A, 2001. 98(2): p. 392-4. 4. Sharma, S., T.K. Kelly, and P.A. Jones, Epigenetics in Cancer. Carcinogenesis, 2009. 5. Qiu, J., Epigenetics: unfinished symphony. Nature, 2006. 441(7090): p. 143-5. 6. Bird, A., DNA methylation patterns and epigenetic memory. Genes Dev, 2002. 16(1): p. 6-21. 7. Jones, P.A. and S.B. Baylin, The fundamental role of epigenetic events in cancer. Nat Rev Genet, 2002. 3(6): p. 415-28. 8. Wang, Y. and F.C. Leung, An evaluation of new criteria for CpG islands in the human genome as gene markers. Bioinformatics, 2004. 20(7): p. 1170-7. 9. Rimel, B.J., et al., Absence of MGMT promoter methylation in endometrial cancer. Gynecol Oncol, 2009. 112(1): p. 224-8. 10. Egger, G., et al., Epigenetics in human disease and prospects for epigenetic therapy. Nature, 2004. 429(6990): p. 457-63. 11. Feinberg, A.P. and B. Vogelstein, Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature, 1983. 301(5895): p. 89-92. 12. Herman, J.G. and S.B. Baylin, Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med, 2003. 349(21): p. 2042-54. 13. Clark, S.J., J. Harrison, and P.L. Molloy, Sp1 binding is inhibited by (m)Cp(m)CpG methylation. Gene, 1997. 195(1): p. 67-71. 14. Prendergast, G.C. and E.B. Ziff, Methylation-sensitive sequence-specific DNA binding by the c-Myc basic region. Science, 1991. 251(4990): p. 186-9. 15. Greger, V., et al., Epigenetic changes may contribute to the formation and spontaneous regression of retinoblastoma. Hum Genet, 1989. 83(2): p. 155-8. 16. Jain, N., A. Rossi, and G. Garcia-Manero, Epigenetic therapy of leukemia: An update. Int J Biochem Cell Biol, 2009. 41(1): p. 72-80. 17. Mai, S. and Y. Garini, The significance of telomeric aggregates in the interphase nuclei of tumor cells. J Cell Biochem, 2006. 97(5): p. 904-15. 18. Esteller, M., Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet, 2007. 16 Spec No 1: p. R50-9. 19. Li, E., C. Beard, and R. Jaenisch, Role for DNA methylation in genomic imprinting. Nature, 1993. 366(6453): p. 362-5. 20. Li, E., T.H. Bestor, and R. Jaenisch, Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell, 1992. 69(6): p. 915-26. 21. Bestor, T.H., The DNA methyltransferases of mammals. Hum Mol Genet, 2000. 9(16): p. 2395-402. 22. Hermann, A., R. Goyal, and A. Jeltsch, The Dnmt1 DNA-(cytosine-C5)-methyltransferase methylates DNA processively with high preference for hemimethylated target sites. J Biol Chem, 2004. 279(46): p. 48350-9. 23. Robertson, A.K., et al., Effects of chromatin structure on the enzymatic and DNA binding functions of DNA methyltransferases DNMT1 and Dnmt3a in vitro. Biochem Biophys Res Commun, 2004. 322(1): p. 110-8. 24. Chuang, L.S., et al., Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1. Science, 1997. 277(5334): p. 1996-2000. 25. Okano, M., S. Xie, and E. Li, Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet, 1998. 19(3): p. 219-20. 26. Kunert, N., et al., A Dnmt2-like protein mediates DNA methylation in Drosophila. Development, 2003. 130(21): p. 5083-90. 27. Xie, S., et al., Cloning, expression and chromosome locations of the human DNMT3 gene family. Gene, 1999. 236(1): p. 87-95. 28. Kelly, T.L. and J.M. Trasler, Reproductive epigenetics. Clin Genet, 2004. 65(4): p. 247-60. 29. Catalano, V., et al., Gastric cancer. Crit Rev Oncol Hematol, 2009. 30. Correa, P. and V.W. Chen, Gastric cancer. Cancer Surv, 1994. 19-20: p. 55-76. 31. Kelley, J.R. and J.M. Duggan, Gastric cancer epidemiology and risk factors. J Clin Epidemiol, 2003. 56(1): p. 1-9. 32. Sjodahl, K., et al., Smoking and alcohol drinking in relation to risk of gastric cancer: a population-based, prospective cohort study. Int J Cancer, 2007. 120(1): p. 128-32. 33. Sarbia, M., et al., Association between NAD(P)H: quinone oxidoreductase 1 (NQ01) inactivating C609T polymorphism and adenocarcinoma of the upper gastrointestinal tract. Int J Cancer, 2003. 107(3): p. 381-6. 34. Nelson, J.B., et al., Methylation of the 5' CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res, 1997. 57(1): p. 35-7. 35. Konturek, P.C., S.J. Konturek, and T. Brzozowski, Helicobacter pylori infection in gastric cancerogenesis. J Physiol Pharmacol, 2009. 60(3): p. 3-21. 36. Yuasa, K., et al., Effects of lifestyle habits and eating meals together with the family on the prevalence of obesity among school children in Tokushima, Japan: a cross-sectional questionnaire-based survey. J Med Invest, 2008. 55(1-2): p. 71-7. 37. Pectasides, D., et al., CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma. Am J Clin Oncol, 1997. 20(4): p. 348-53. 38. Stadtlander, C.T. and J.W. Waterbor, Molecular epidemiology, pathogenesis and prevention of gastric cancer. Carcinogenesis, 1999. 20(12): p. 2195-208. 39. Yasui, W., et al., Molecular diagnosis of gastric cancer: present and future. Gastric Cancer, 2001. 4(3): p. 113-21. 40. Yasui, W., et al., Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer, 2005. 8(2): p. 86-94. 41. Iida, S., et al., Alterations and hypermethylation of the p14(ARF) gene in gastric cancer. Int J Cancer, 2000. 87(5): p. 654-8. 42. Oue, N., et al., Promoter hypermethylation of MGMT is associated with protein loss in gastric carcinoma. Int J Cancer, 2001. 93(6): p. 805-9. 43. Tsuchiya, T., et al., Distinct methylation patterns of two APC gene promoters in normal and cancerous gastric epithelia. Oncogene, 2000. 19(32): p. 3642-6. 44. Johnson, I.T. and N.J. Belshaw, Environment, diet and CpG island methylation: epigenetic signals in gastrointestinal neoplasia. Food Chem Toxicol, 2008. 46(4): p. 1346-59. 45. Ozawa, S., H. Kamiya, and K. Tsuzuki, Glutamate receptors in the mammalian central nervous system. Prog Neurobiol, 1998. 54(5): p. 581-618. 46. Dingledine, R., et al., Amino acid receptors and uptake systems in the mammalian central nervous system. Crit Rev Neurobiol, 1988. 4(1): p. 1-96. 47. Pin, J.P., T. Galvez, and L. Prezeau, Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol Ther, 2003. 98(3): p. 325-54. 48. Nakanishi, S., Molecular diversity of glutamate receptors and implications for brain function. Science, 1992. 258(5082): p. 597-603. 49. Hollmann, M. and S. Heinemann, Cloned glutamate receptors. Annu Rev Neurosci, 1994. 17: p. 31-108. 50. Pin, J.P. and R. Duvoisin, The metabotropic glutamate receptors: structure and functions. Neuropharmacology, 1995. 34(1): p. 1-26. 51. Anwyl, R., Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brain Res Brain Res Rev, 1999. 29(1): p. 83-120. 52. Selimi, F., et al., Bax and p53 are differentially involved in the regulation of caspase-3 expression and activation during neurodegeneration in Lurcher mice. C R Acad Sci III, 2000. 323(11): p. 967-73. 53. Dingledine, R., et al., The glutamate receptor ion channels. Pharmacol Rev, 1999. 51(1): p. 7-61. 54. Bettler, B., et al., Cloning of a novel glutamate receptor subunit, GluR5: expression in the nervous system during development. Neuron, 1990. 5(5): p. 583-95. 55. Bettler, B. and C. Mulle, Review: neurotransmitter receptors. II. AMPA and kainate receptors. Neuropharmacology, 1995. 34(2): p. 123-39. 56. de Groot, J.F., et al., Knockdown of GluR1 expression by RNA interference inhibits glioma proliferation. J Neurooncol, 2008. 88(2): p. 121-33. 57. Kirchgessner, A.L., Glutamate in the enteric nervous system. Curr Opin Pharmacol, 2001. 1(6): p. 591-6. 58. Nowak, L., et al., Magnesium gates glutamate-activated channels in mouse central neurones. Nature, 1984. 307(5950): p. 462-5. 59. MacDermott, A.B., et al., NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones. Nature, 1986. 321(6069): p. 519-22. 60. Kim, M.S., et al., N-Methyl-D-Aspartate Receptor Type 2B Is Epigenetically Inactivated and Exhibits Tumor-Suppressive Activity in Human Esophageal Cancer. Cancer Res, 2006. 66(7): p. 3409-3418. 61. Liu, J.W., et al., Quantitative hypermethylation of NMDAR2B in human gastric cancer. Int J Cancer, 2007. 121(9): p. 1994-2000. 62. Kim, M.S., et al., The N-methyl-D-aspartate receptor type 2A is frequently methylated in human colorectal carcinoma and suppresses cell growth. Oncogene, 2008. 27(14): p. 2045-54. 63. Seeburg, P.H., The TINS/TiPS Lecture. The molecular biology of mammalian glutamate receptor channels. Trends Neurosci, 1993. 16(9): p. 359-65. 64. Egebjerg, J., et al., Cloning of a cDNA for a glutamate receptor subunit activated by kainate but not AMPA. Nature, 1991. 351(6329): p. 745-8. 65. Sommer, B., et al., A glutamate receptor channel with high affinity for domoate and kainate. Embo J, 1992. 11(4): p. 1651-6. 66. Paschen, W., et al., Human GluR6 kainate receptor (GRIK2): molecular cloning, expression, polymorphism, and chromosomal assignment. Genomics, 1994. 20(3): p. 435-40. 67. Barbon, A., I. Vallini, and S. Barlati, Genomic organization of the human GRIK2 gene and evidence for multiple splicing variants. Gene, 2001. 274(1-2): p. 187-97. 68. Li, G., R.E. Oswald, and L. Niu, Channel-opening kinetics of GluR6 kainate receptor. Biochemistry, 2003. 42(42): p. 12367-75. 69. Paternain, A.V., et al., GluR5 and GluR6 kainate receptor subunits coexist in hippocampal neurons and coassemble to form functional receptors. J Neurosci, 2000. 20(1): p. 196-205. 70. Paschen, W., J. Schmitt, and A. Uto, RNA editing of glutamate receptor subunits GluR2, GluR5 and GluR6 in transient cerebral ischemia in the rat. J Cereb Blood Flow Metab, 1996. 16(4): p. 548-56. 71. Zeng, W., et al., Genetic analysis of the GRIK2 modifier effect in Huntington's disease. BMC Neurosci, 2006. 7: p. 62. 72. Motazacker, M.M., et al., A defect in the ionotropic glutamate receptor 6 gene (GRIK2) is associated with autosomal recessive mental retardation. Am J Hum Genet, 2007. 81(4): p. 792-8. 73. Dutta, S., et al., Glutamate receptor 6 gene (GluR6 or GRIK2) polymorphisms in the Indian population: a genetic association study on autism spectrum disorder. Cell Mol Neurobiol, 2007. 27(8): p. 1035-47. 74. Shaltiel, G., et al., Evidence for the involvement of the kainate receptor subunit GluR6 (GRIK2) in mediating behavioral displays related to behavioral symptoms of mania. Mol Psychiatry, 2008. 13(9): p. 858-72. 75. Bah, J., et al., Maternal transmission disequilibrium of the glutamate receptor GRIK2 in schizophrenia. Neuroreport, 2004. 15(12): p. 1987-91. 76. Huang, T.H., M.R. Perry, and D.E. Laux, Methylation profiling of CpG islands in human breast cancer cells. Hum Mol Genet, 1999. 8(3): p. 459-70. 77. Wei, S.H., et al., Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res, 2002. 8(7): p. 2246-52. 78. Yan, P.S., et al., Applications of CpG island microarrays for high-throughput analysis of DNA methylation. J Nutr, 2002. 132(8 Suppl): p. 2430S-2434S. 79. Chan, M.W., et al., Hypermethylation of 18S and 28S ribosomal DNAs predicts progression-free survival in patients with ovarian cancer. Clin Cancer Res, 2005. 11(20): p. 7376-83. 80. Buffart, T.E., et al., MAL promoter hypermethylation as a novel prognostic marker in gastric cancer. Br J Cancer, 2008. 99(11): p. 1802-7. 81. Yuan, B.Z., et al., Cloning, characterization, and chromosomal localization of a gene frequently deleted in human liver cancer (DLC-1) homologous to rat RhoGAP. Cancer Res, 1998. 58(10): p. 2196-9. 82. Kim, T.Y., et al., Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. Oncogene, 2003. 22(25): p. 3943-51. 83. Sinclair, P.B., et al., A fluorescence in situ hybridization map of 6q deletions in acute lymphocytic leukemia: identification and analysis of a candidate tumor suppressor gene. Cancer Res, 2004. 64(12): p. 4089-98. 84. Coussen, F., et al., Recruitment of the kainate receptor subunit glutamate receptor 6 by cadherin/catenin complexes. J Neurosci, 2002. 22(15): p. 6426-36. 85. Poplawski, T., et al., Promoter methylation of cancer-related genes in gastric carcinoma. Exp Oncol, 2008. 30(2): p. 112-6. 86. Kolligs, F.T., G. Bommer, and B. Goke, Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis. Digestion, 2002. 66(3): p. 131-44. 87. Choi, I.S. and T.T. Wu, Epigenetic alterations in gastric carcinogenesis. Cell Res, 2005. 15(4): p. 247-54. 88. Seng, T.J., et al., The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation. Oncogene, 2006. 89. Goodison, S., et al., The RhoGAP protein DLC-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res, 2005. 65(14): p. 6042-53. 90. Ng, I.O., et al., DLC-1 is deleted in primary hepatocellular carcinoma and exerts inhibitory effects on the proliferation of hepatoma cell lines with deleted DLC-1. Cancer Res, 2000. 60(23): p. 6581-4. 91. Shin, S.S., J.J. Martino, and S. Chen, Metabotropic glutamate receptors (mGlus) and cellular transformation. Neuropharmacology, 2008. 55(4): p. 396-402. 92. Watanabe, K., et al., The NMDA receptor NR2A subunit regulates proliferation of MKN45 human gastric cancer cells. Biochem Biophys Res Commun, 2008. 367(2): p. 487-90. 93. Muller, T., et al., Regulation of epithelial cell migration and tumor formation by beta-catenin signaling. Exp Cell Res, 2002. 280(1): p. 119-33. 94. Kim, S.J., et al., AMPA, not NMDA, activates RhoA GTPases and subsequently phosphorylates moesin. Exp Mol Med, 2004. 36(1): p. 98-102. 95. Niggli, V. and J. Rossy, Ezrin/radixin/moesin: versatile controllers of signaling molecules and of the cortical cytoskeleton. Int J Biochem Cell Biol, 2008. 40(3): p. 344-9. 96. Ganor, Y., et al., Human T cells express a functional ionotropic glutamate receptor GluR3, and glutamate by itself triggers integrin-mediated adhesion to laminin and fibronectin and chemotactic migration. J Immunol, 2003. 170(8): p. 4362-72. 97. Barbon, A., et al., Human GluR6c, a functional splicing variants of GluR6, is mainly expressed in non-nervous cells. Neurosci Lett, 2008. 434(1): p. 77-82. 98. Caruso, M.L. and L. Fucci, Histological identification of Helicobacter pylori in early and advanced gastric cancer. J Clin Gastroenterol, 1990. 12(5): p. 601-2. 99. Chan, A.O., et al., Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer. Gut, 2003. 52(4): p. 502-6. 100. Kitajima, Y., et al., Helicobacter pylori infection is an independent risk factor for Runx3 methylation in gastric cancer. Oncol Rep, 2008. 19(1): p. 197-202. 101. Huang, L., et al., Infrequent COX-2 expression due to promoter hypermethylation in gastric cancers in Dalian, China. Hum Pathol, 2006. 37(12): p. 1557-67. 102. Sellar, G.C., et al., OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet, 2003. 34(3): p. 337-43. 103. Costa, F.F., et al., Epigenetic silencing of the adhesion molecule ADAM23 is highly frequent in breast tumors. Oncogene, 2004. 23(7): p. 1481-8. 104. Miotto, E., et al., Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer. Cancer Res, 2004. 64(22): p. 8156-9. 105. Sato, M., et al., The H-cadherin (CDH13) gene is inactivated in human lung cancer. Hum Genet, 1998. 103(1): p. 96-101. 106. Ahuja, N., et al., Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res, 1997. 57(16): p. 3370-4. 107. Zochbauer-Muller, S., et al., Aberrant promoter methylation of multiple genes in non-small cell lung cancers. Cancer Res, 2001. 61(1): p. 249-55. 108. Kovarik, A., et al., Drug-induced hypomethylation of a posttranscriptionally silenced transgene locus of tobacco leads to partial release of silencing. FEBS Lett, 2000. 467(1): p. 47-51. 109. Xu, X.L., et al., Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers. Cancer Res, 2001. 61(21): p. 7943-9. 110. Du, P., et al., Methylation of PTCH1a gene in a subset of gastric cancers. World J Gastroenterol, 2009. 15(30): p. 3799-806. 111. Dong, W., et al., Frequent promoter hypermethylation and transcriptional downregulation of BTG4 gene in gastric cancer. Biochem Biophys Res Commun, 2009. 387(1): p. 132-8. 112. Wang, Y., et al., CMTM3, located at the critical tumor suppressor locus 16q22.1, is silenced by CpG methylation in carcinomas and inhibits tumor cell growth through inducing apoptosis. Cancer Res, 2009. 69(12): p. 5194-201. 113. Esteller, M., et al., Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res, 2000. 60(1): p. 129-33. 114. Baur, A.S., et al., Frequent methylation silencing of p15(INK4b) (MTS2) and p16(INK4a) (MTS1) in B-cell and T-cell lymphomas. Blood, 1999. 94(5): p. 1773-81. 115. Akhtar, M., et al., Promoter methylation regulates Helicobacter pylori-stimulated cyclooxygenase-2 expression in gastric epithelial cells. Cancer Res, 2001. 61(6): p. 2399-403. 116. Smith, P., N. Syed, and T. Crook, Epigenetic inactivation implies a tumor suppressor function in hematologic malignancies for Polo-like kinase 2 but not Polo-like kinase 3. Cell Cycle, 2006. 5(12): p. 1262-4. 117. Tanaka, H., et al., Methylation of the 5' CpG island of the FHIT gene is closely associated with transcriptional inactivation in esophageal squamous cell carcinomas. Cancer Res, 1998. 58(15): p. 3429-34. 118. Li, B., et al., CpG methylation as a basis for breast tumor-specific loss of NES1/kallikrein 10 expression. Cancer Res, 2001. 61(21): p. 8014-21. 119. Wang, L.J., et al., ZIC1 is downregulated through promoter hypermethylation in gastric cancer. Biochem Biophys Res Commun, 2009. 379(4): p. 959-63. 120. Waki, T., et al., Promoter methylation status of DAP-kinase and RUNX3 genes in neoplastic and non-neoplastic gastric epithelia. Cancer Sci, 2003. 94(4): p. 360-4. 121. Yoshikawa, H., et al., SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet, 2001. 28(1): p. 29-35. 122. Herman, J.G., et al., Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A, 1998. 95(12): p. 6870-5. 123. Cairns-Smith, S. and P. Karran, Epigenetic silencing of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in Mex- human cells. Cancer Res, 1992. 52(19): p. 5257-63. 124. Kang, G.H., et al., Epstein-barr virus-positive gastric carcinoma demonstrates frequent aberrant methylation of multiple genes and constitutes CpG island methylator phenotype-positive gastric carcinoma. Am J Pathol, 2002. 160(3): p. 787-94. 125. Esteller, M., et al., A gene hypermethylation profile of human cancer. Cancer Res, 2001. 61(8): p. 3225-9. 126. Wong, C.M., et al., Genetic and epigenetic alterations of DLC-1 gene in hepatocellular carcinoma. Cancer Res, 2003. 63(22): p. 7646-51. 127. van Doorn, R., et al., Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73. J Clin Oncol, 2005. 23(17): p. 3886-96. 128. Hu, X.T., et al., Phospholipase C delta 1 is a novel 3p22.3 tumor suppressor involved in cytoskeleton organization, with its epigenetic silencing correlated with high-stage gastric cancer. Oncogene, 2009. 28(26): p. 2466-75. 129. Nakayama, M., et al., Hypomethylation status of CpG sites at the promoter region and overexpression of the human MDR1 gene in acute myeloid leukemias. Blood, 1998. 92(11): p. 4296-307. 130. Chen, M., et al., Integrin alpha6beta4 controls the expression of genes associated with cell motility, invasion, and metastasis, including S100A4/metastasin. J Biol Chem, 2009. 284(3): p. 1484-94. 131. Kaneda, A., et al., Lysyl oxidase is a tumor suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers. Cancer Res, 2004. 64(18): p. 6410-5. 132. Hiltunen, M.O., et al., Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma. Int J Cancer, 1997. 70(6): p. 644-8. 133. Dammann, R., et al., Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet, 2000. 25(3): p. 315-9. 134. Sato, N., et al., Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers. Gastroenterology, 2006. 130(2): p. 548-65. 135. Wang, Y., et al., Survey of differentially methylated promoters in prostate cancer cell lines. Neoplasia, 2005. 7(8): p. 748-60. 136. Moinova, H.R., et al., HLTF gene silencing in human colon cancer. Proc Natl Acad Sci U S A, 2002. 99(7): p. 4562-7. 137. Byun, D.S., et al., Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas. Cancer Res, 2003. 63(21): p. 7068-75. 138. Honda, T., et al., Hypermethylation of the TSLC1 gene promoter in primary gastric cancers and gastric cancer cell lines. Jpn J Cancer Res, 2002. 93(8): p. 857-60. 139. Jung, Y., et al., Gene silencing of TSPYL5 mediated by aberrant promoter methylation in gastric cancers. Lab Invest, 2008. 88(2): p. 153-60. 140. Arisawa, T., et al., The influence of promoter polymorphism of nuclear factor-erythroid 2-related factor 2 gene on the aberrant DNA methylation in gastric epithelium. Oncol Rep, 2008. 19(1): p. 211-6. 141. Jang, T.J., Y.S. Ji, and K.H. Jung, Decreased expression of 15-hydroxyprostaglandin dehydrogenase in gastric carcinomas. Yonsei Med J, 2008. 49(6): p. 917-22. 142. Sakata, M., et al., Methylation of HACE1 in gastric carcinoma. Anticancer Res, 2009. 29(6): p. 2231-3. 143. Kang, G.H., et al., DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab Invest, 2008. 88(2): p. 161-70. 144. Issa, J.P., et al., Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res, 2001. 61(9): p. 3573-7. 145. Shiraishi, M., et al., A comprehensive catalog of CpG islands methylated in human lung adenocarcinomas for the identification of tumor suppressor genes. Oncogene, 2002. 21(23): p. 3804-13. 146. Arima, T., et al., The human HYMAI/PLAGL1 differentially methylated region acts as an imprint control region in mice. Genomics, 2006. 88(5): p. 650-8. 147. Hiltunen, M.O., et al., Hypermethylation of the WT1 and calcitonin gene promoter regions at chromosome 11p in human colorectal cancer. Br J Cancer, 1997. 76(9): p. 1124-30. 148. Sonoda, I., et al., Frequent silencing of low density lipoprotein receptor-related protein 1B (LRP1B) expression by genetic and epigenetic mechanisms in esophageal squamous cell carcinoma. Cancer Res, 2004. 64(11): p. 3741-7. 149. Hartsough, M.T., et al., Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition. Cancer Res, 2001. 61(5): p. 2320-7. 150. Lin, C.S., et al., Differential regulation of human T-plastin gene in leukocytes and non-leukocytes: identification of the promoter, enhancer, and CpG island. DNA Cell Biol, 1999. 18(1): p. 27-37. 151. Akashi, H., et al., Growth-suppressive effect of non-steroidal anti-inflammatory drugs on 11 colon-cancer cell lines and fluorescence differential display of genes whose expression is influenced by sulindac. Int J Cancer, 2000. 88(6): p. 873-80. 152. Leung, S.Y., et al., hMLH1 promoter methylation and lack of hMLH1 expression in sporadic gastric carcinomas with high-frequency microsatellite instability. Cancer Res, 1999. 59(1): p. 159-64. 153. Yamamoto, E., et al., LINE-1 hypomethylation is associated with increased CpG island methylation in Helicobacter pylori-related enlarged-fold gastritis. Cancer Epidemiol Biomarkers Prev, 2008. 17(10): p. 2555-64. 154. Schildhaus, H.U., et al., Promoter hypermethylation of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in adenocarcinomas of the esophagus, esophagogastric junction and proximal stomach. Int J Oncol, 2005. 26(6): p. 1493-500. 155. Huang, W., et al., Downregulation and CpG island hypermethylation of NES1/hK10 gene in the pathogenesis of human gastric cancer. Cancer Lett, 2007. 251(1): p. 78-85. 156. Yamashita, S., et al., Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci, 2006. 97(1): p. 64-71. 157. Yuan, B.Z., et al., DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene, 2004. 23(7): p. 1405-11.
|